Glycoprotein and Antibody-Drug Conjugate Sequence Listings in Patent Applications

Introduction

The rapid evolution of biotechnology has transformed the pharmaceutical landscape, with glycoproteins and antibody-drug conjugates (ADCs) emerging as some of the most valuable and innovative therapeutic modalities. From monoclonal antibodies used in oncology and autoimmune disorders to sophisticated ADCs that selectively deliver cytotoxic payloads to cancer cells, these biologics represent a significant portion of current pharmaceutical research and patent activity. As innovators race to secure intellectual property protection for these complex molecules, one critical aspect of patent drafting often becomes a focal point of examination and compliance: the sequence listing. Patent offices worldwide require applicants to disclose biological sequences in a standardized format to ensure clarity, reproducibility and accessibility. However, sequence listing requirements become increasingly complex when dealing with glycoproteins, engineered antibodies, fusion proteins and antibody-drug conjugates that contain both biological and non-biological components. Failure to properly disclose sequence information can lead to formal objections, enablement challenges, written description issues and in some cases, jeopardize patent rights altogether. Understanding how sequence listing rules apply to glycoproteins and ADCs is therefore essential for biotechnology companies, patent attorneys, research institutions and pharmaceutical innovators.

Understanding Sequence Listings in Patent Applications

A sequence listing is a standardized document that presents nucleotide and amino acid sequences referenced in a patent application.

The primary objectives of sequence listings are to:

Sequence listings have become increasingly important as biotechnology patents often depend on precise molecular definitions rather than broad functional descriptions.

For biologic inventions, the sequence listing frequently serves as a foundational disclosure supporting patent claims.

The Transition to WIPO ST.26

Modern sequence listing practice is governed by the World Intellectual Property Organization (WIPO) Standard ST.26.

ST.26 replaced the earlier ST.25 standard and introduced a structured XML-based format designed to improve data consistency and machine readability.

Under ST.26:

The transition has significant implications for applicants working with glycoproteins and ADC-related inventions.

Glycoproteins and Patent Protection

Glycoproteins are proteins that contain covalently attached carbohydrate structures known as glycans.

Examples include:

In many cases, both the amino acid sequence and glycosylation profile contribute to the biological activity of the molecule.

Patent claims may focus on:

This raises important disclosure questions regarding what information belongs in the sequence listing and what must be described elsewhere in the specification.

What Must Be Included for Glycoproteins?

Sequence listings primarily capture the amino acid sequence of the protein.

For example:

The amino acid sequence itself generally appears in the sequence listing.

However, carbohydrate structures attached to the protein are not represented as amino acid residues and therefore are typically not included as part of the sequence itself.

Instead, glycosylation-related information is usually disclosed in:

Applicants should clearly identify:

This information often becomes critical for satisfying written description and enablement requirements.

Patent Challenges Associated with Glycoprotein Disclosure

Written Description Requirements

A recurring issue in biotechnology patent prosecution involves demonstrating possession of the claimed invention.

Merely disclosing a protein sequence may not adequately support claims directed to:

Patent offices and courts may require evidence showing that the applicant possessed the claimed glycosylated structures at the time of filing.

Enablement Considerations

Enablement requires teaching a skilled person how to make and use the invention without undue experimentation.

For glycoproteins, applicants often need to disclose:

Because glycosylation can vary significantly across expression systems, detailed disclosure becomes particularly important.

Antibody-Drug Conjugates (ADCs): A Unique Patenting Challenge

Antibody-drug conjugates combine:

  1. A targeting antibody
  2. A chemical linker
  3. A therapeutic payload

These multifunctional molecules represent one of the most sophisticated classes of biologic therapeutics.

Examples of ADC targets include:

The antibody component provides selective targeting, while the conjugated drug delivers therapeutic activity directly to diseased cells.

Because ADCs contain both biological and synthetic components, sequence listing requirements become more nuanced.

Sequence Listing Requirements for ADCs

The biological portions of an ADC generally require sequence disclosure.

These may include:

The antibody sequence information is typically included in the sequence listing.

However, non-biological elements are generally excluded.

Examples include:

These components are normally described elsewhere in the patent specification.

Disclosing Antibody Variable Regions and CDRs

Many ADC patents focus on proprietary antibody targeting systems.

Applicants frequently disclose:

Including detailed sequence information can support claims directed to:

Accurate sequence disclosure strengthens both validity and enforceability.

Sequence Variants and Genus Claims

Biotechnology applicants often seek protection extending beyond a single sequence.

Patent claims may encompass:

Supporting such claims requires careful drafting.

Applicants should consider disclosing:

Insufficient disclosure may expose broad claims to written description challenges.

ADC-Specific Disclosure Strategies

Given the complexity of ADCs, robust patent applications often include:

Antibody Sequences

Complete sequence listings for all relevant chains.

Conjugation Sites

Identification of attachment locations.

Drug-to-Antibody Ratio (DAR)

Characterization of payload loading.

Linker Chemistry

Descriptions of linker structures and mechanisms.

Payload Structures

Detailed chemical disclosures.

Functional Data

Evidence demonstrating biological activity.

Together, these disclosures provide a comprehensive foundation for patent protection.

International Patent Considerations

Sequence listing requirements are increasingly harmonized, but applicants must remain aware of jurisdiction-specific practices.

Major patent offices including:

generally accept ST.26-compliant sequence listings.

However, substantive requirements regarding written description, enablement and claim scope may vary.

Applicants pursuing global protection should ensure consistency between:

Discrepancies can create prosecution challenges across jurisdictions.

Common Mistakes in Glycoprotein and ADC Patent Filings

Patent applicants frequently encounter problems such as:

Omitting Critical Sequences

Missing antibody chains or variable regions.

Inconsistent Sequence References

Differences between claims, examples and sequence listings.

Inadequate Glycosylation Disclosure

Failure to describe important glycan characteristics.

Overreliance on Functional Language

Broad functional claims unsupported by sufficient sequence data.

Incomplete Variant Support

Insufficient disclosure for broad genus claims.

ST.26 Formatting Errors

Technical deficiencies in XML sequence submissions.

Addressing these issues early can prevent costly prosecution delays.

Best Practices for Patent Applicants

To strengthen glycoprotein and ADC patent applications, applicants should:

  1. Prepare ST.26-compliant sequence listings from the outset.
  2. Include complete amino acid and nucleotide sequences.
  3. Clearly identify glycosylation sites and relevant glycan characteristics.
  4. Provide extensive biological characterization data.
  5. Disclose multiple embodiments and sequence variants.
  6. Align claims closely with supporting sequence information.
  7. Coordinate scientific and patent teams during drafting.
  8. Review sequence listings carefully for consistency and accuracy.

These practices can significantly improve patent robustness and examination outcomes.

Conclusion

As biologic therapeutics become increasingly sophisticated, sequence listings play an ever more important role in patent protection. Glycoproteins and antibody-drug conjugates present unique disclosure challenges because they combine precisely defined biological sequences with complex structural and functional characteristics that extend beyond the sequence itself. While amino acid and nucleotide sequences remain central to patent disclosure under WIPO ST.26, successful patent applications also require comprehensive descriptions of glycosylation profiles, conjugation strategies, linker chemistry, payload structures and biological performance. A well-prepared sequence listing, combined with a robust written specification, helps establish compliance with patent office requirements while supporting broad and defensible intellectual property rights. For biotechnology innovators operating in an increasingly competitive therapeutic landscape, mastering sequence listing requirements is not simply a procedural necessity – it is a critical component of building strong, enforceable patent portfolios for next-generation biologics.

Leave a Reply

Your email address will not be published. Required fields are marked *